Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 9;10(3):e004190. doi: 10.1136/jitc-2021-004190

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Genomic landscape of the primary, metastatic, and recurrent lesions. (A) Overview of the clinical and sample collection timeline for the analysis performed in this study. (B) The number of non-silent mutations shared within and across samples is shown (see also online supplemental table S2). (C) The copy number landscape is shown, depicting copy number gains (red) and losses (blue), detected by WES, the primary, metastasis, and recurrence samples. ACT, adoptive cell transfer; Cy, cyclophosphamide; CN, copy number; DC, dendritic cell; Flu, fludarabine; IL, interleukin; Ipi, ipilimumab; LD, low-dose; PET, positron emission tomography; TCR, T-cell receptor; WES, whole-exome sequencing.